标题
Drug rechallenge and treatment beyond progression—implications for drug resistance
作者
关键词
-
出版物
Nature Reviews Clinical Oncology
Volume 10, Issue 10, Pages 571-587
出版商
Springer Nature
发表日期
2013-09-03
DOI
10.1038/nrclinonc.2013.158
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Development of a Resistance-like Phenotype to Sorafenib by Human Hepatocellular Carcinoma Cells Is Reversible and Can Be Delayed by Metronomic UFT Chemotherapy
- (2015) Terence C. Tang et al. NEOPLASIA
- Intermittent and continuous imatinib in a human GIST xenograft model carryingKITexon 17 resistance mutation D816H
- (2013) Mona-Elisabeth Revheim et al. ACTA ONCOLOGICA
- Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study
- (2013) D. M. Ross et al. BLOOD
- A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma
- (2013) Maria T. Petrucci et al. BRITISH JOURNAL OF HAEMATOLOGY
- A Model of Postsurgical Advanced Metastatic Breast Cancer More Accurately Replicates the Clinical Efficacy of Antiangiogenic Drugs
- (2013) E. Guerin et al. CANCER RESEARCH
- Does T790M Disappear? Successful Gefitinib Rechallenge After T790M Disappearance in a Patient With EGFR-Mutant Non–Small-Cell Lung Cancer
- (2013) Akito Hata et al. Journal of Thoracic Oncology
- EGFR-tyrosine kinase inhibitor treatment beyond progression in long-term Caucasian responders to erlotinib in advanced non-small cell lung cancer: A case–control study of overall survival
- (2013) M. Faehling et al. LUNG CANCER
- Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance
- (2013) Meghna Das Thakur et al. NATURE
- Transient Sunitinib Resistance in Gastrointestinal Stromal Tumors
- (2013) Raffaella Bracci et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cancer Genome Landscapes
- (2013) B. Vogelstein et al. SCIENCE
- Influence of imatinib interruption and rechallenge on the residual disease in patients with advanced GIST: results of the BFR14 prospective French Sarcoma Group randomised, phase III trial
- (2012) A. Patrikidou et al. ANNALS OF ONCOLOGY
- Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance?
- (2012) D. Santini et al. ANNALS OF ONCOLOGY
- Sorafenib rechallenge in patients with metastatic renal cell carcinoma
- (2012) Masahiro Nozawa et al. BJU INTERNATIONAL
- Rational indication for docetaxel rechallenge in metastatic castration-resistant prostate cancer
- (2012) Matthias M. Heck et al. BJU INTERNATIONAL
- Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients
- (2012) D A Reardon et al. BRITISH JOURNAL OF CANCER
- Reversal of ATP-binding cassette drug transporter activity to modulate chemoresistance: why has it failed to provide clinical benefit?
- (2012) Man Yu et al. CANCER AND METASTASIS REVIEWS
- A Pooled Analysis of 2618 Patients Treated With Trastuzumab Beyond Progression for Advanced Breast Cancer
- (2012) Fausto Petrelli et al. Clinical Breast Cancer
- Bevacizumab rechallenge after first line maintenance bevacizumab
- (2012) Panagiotis A. Konstantinopoulos et al. GYNECOLOGIC ONCOLOGY
- Six Cycles of Doxorubicin and Cyclophosphamide or Paclitaxel Are Not Superior to Four Cycles As Adjuvant Chemotherapy for Breast Cancer in Women With Zero to Three Positive Axillary Nodes: Cancer and Leukemia Group B 40101
- (2012) Lawrence N. Shulman et al. JOURNAL OF CLINICAL ONCOLOGY
- Overall Survival Benefit With Lapatinib in Combination With Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer: Final Results From the EGF104900 Study
- (2012) Kimberly L. Blackwell et al. JOURNAL OF CLINICAL ONCOLOGY
- Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Beyond Progressive Disease: A Retrospective Analysis for Japanese Patients with Activating EGFR Mutations
- (2012) Kenichi Nishie et al. Journal of Thoracic Oncology
- Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial
- (2012) Jaafar Bennouna et al. LANCET ONCOLOGY
- Retreatment of gefitinib in patients with non-small-cell lung cancer who previously controlled to gefitinib: A single-arm, open-label, phase II study
- (2012) In-Jae Oh et al. LUNG CANCER
- Clonal evolution in cancer
- (2012) Mel Greaves et al. NATURE
- Treatment selection in metastatic renal cell carcinoma: expert consensus
- (2012) Bernard Escudier et al. Nature Reviews Clinical Oncology
- Variable Clonal Repopulation Dynamics Influence Chemotherapy Response in Colorectal Cancer
- (2012) A. Kreso et al. SCIENCE
- A Validated Tumorgraft Model Reveals Activity of Dovitinib Against Renal Cell Carcinoma
- (2012) S. Sivanand et al. Science Translational Medicine
- LGR5-Positive Colon Cancer Stem Cells Interconvert with Drug-Resistant LGR5-Negative cells and are Capable of Tumor Reconstitution
- (2012) Shinta Kobayashi et al. STEM CELLS
- Successful alemtuzumab retreatment in progressive B-cell chronic lymphocytic leukemia: a multicenter survey in 30 patients
- (2011) Michael Fiegl et al. ANNALS OF HEMATOLOGY
- Patterns of Care, Prognosis, and Survival in Patients with Metastatic Gastrointestinal Stromal Tumors (GIST) Refractory to First-Line Imatinib and Second-Line Sunitinib
- (2011) Antoine Italiano et al. ANNALS OF SURGICAL ONCOLOGY
- Subsequent chemotherapy reverses acquired tyrosine kinase inhibitor resistance and restores response to tyrosine kinase inhibitor in advanced non-small-cell lung cancer
- (2011) Renhua Guo et al. BMC CANCER
- Increased overall survival independent of RECIST response in metastatic breast cancer patients continuing trastuzumab treatment: evidence from a retrospective study
- (2011) Manuela Campiglio et al. BREAST CANCER RESEARCH AND TREATMENT
- Trastuzumab Treatment in Multiple Lines: Current Data and Future Directions
- (2011) M. Pegram et al. Clinical Breast Cancer
- Outcome of Second-Line Treatment After First-Line Chemotherapy With the GONO FOLFOXIRI Regimen
- (2011) Lorenzo Fornaro et al. Clinical Colorectal Cancer
- Retreatment with erlotinib: Regain of TKI sensitivity following a drug holiday for patients with NSCLC who initially responded to EGFR-TKI treatment
- (2011) A. Becker et al. EUROPEAN JOURNAL OF CANCER
- Response to Imatinib Rechallenge of GIST That Recurs Following Completion of Adjuvant Imatinib Treatment - the First Analysis in the SSGXVIII/AIO Trial Patient Population
- (2011) P. Reichardt et al. EUROPEAN JOURNAL OF CANCER
- Duration of Chemotherapy for Metastatic Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
- (2011) Alessandra Gennari et al. JOURNAL OF CLINICAL ONCOLOGY
- High dose intermittent sorafenib shows improved efficacy over conventional continuous dose in renal cell carcinoma
- (2011) Xiaoen Wang et al. Journal of Translational Medicine
- Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial
- (2011) Richard A Adams et al. LANCET ONCOLOGY
- Cancer Cells Cyclically Lose and Regain Drug-Resistant Highly Tumorigenic Features Characteristic of a Cancer Stem-like Phenotype
- (2011) K. He et al. MOLECULAR CANCER THERAPEUTICS
- Rechallenge with temozolomide in recurrent glioma
- (2011) P. Gaviani et al. NEUROLOGICAL SCIENCES
- Bending the Cost Curve in Cancer Care
- (2011) Thomas J. Smith et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase II Study of Gefitinib Readministration in Patients with Advanced Non-Small Cell Lung Cancer and Previous Response to Gefitinib
- (2011) Hajime Asahina et al. ONCOLOGY
- Bortezomib Retreatment in Relapsed Multiple Myeloma – Results from a Retrospective Multicentre Survey in Germany and Switzerland
- (2011) I. Hrusovsky et al. ONCOLOGY
- Reintroduction of Oxaliplatin: A Viable Approach to the Long-Term Management of Metastatic Colorectal Cancer
- (2011) Axel Grothey ONCOLOGY
- Efficacy of Sunitinib Re-Exposure after Failure of an mTOR Inhibitor in Patients with Metastatic RCC
- (2011) Viktor Grünwald et al. ONKOLOGIE
- Resistance of Renal Cell Carcinoma to Sorafenib Is Mediated by Potentially Reversible Gene Expression
- (2011) Liang Zhang et al. PLoS One
- Reversible Resistance Induced by FLT3 Inhibition: A Novel Resistance Mechanism in Mutant FLT3-Expressing Cells
- (2011) Ellen Weisberg et al. PLoS One
- Optimization of Dosing for EGFR-Mutant Non-Small Cell Lung Cancer with Evolutionary Cancer Modeling
- (2011) J. Chmielecki et al. Science Translational Medicine
- Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
- (2011) L. V. Sequist et al. Science Translational Medicine
- Docetaxel reintroduction in patients with metastatic castration-resistant docetaxel-sensitive prostate cancer: a retrospective multicentre study
- (2010) Jean-Christophe Eymard et al. BJU INTERNATIONAL
- Phase II study of docetaxel re-treatment in docetaxel-pretreated castration-resistant prostate cancer
- (2010) Giuseppe Di Lorenzo et al. BJU INTERNATIONAL
- Sunitinib rechallenge in metastatic renal cell carcinoma patients
- (2010) Ivan N. Zama et al. CANCER
- Phenotypic Heterogeneity among Tumorigenic Melanoma Cells from Patients that Is Reversible and Not Hierarchically Organized
- (2010) Elsa Quintana et al. CANCER CELL
- A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
- (2010) Sreenath V. Sharma et al. CELL
- Reduced Dose and Intermittent Treatment with Lapatinib and Trastuzumab for Potent Blockade of the HER Pathway in HER2/neu-Overexpressing Breast Tumor Xenografts
- (2010) Mothaffar F. Rimawi et al. CLINICAL CANCER RESEARCH
- Chemotherapy Resistance and Retreatment: A Dogma Revisited
- (2010) Aung Naing et al. Clinical Colorectal Cancer
- The interval from the last cycle of docetaxel-based chemotherapy to progression is associated with the efficacy of subsequent docetaxel in patients with prostate cancer
- (2010) Yohann Loriot et al. EUROPEAN JOURNAL OF CANCER
- The therapeutic promise of the cancer stem cell concept
- (2010) Natasha Y. Frank et al. JOURNAL OF CLINICAL INVESTIGATION
- Randomized Study of Lapatinib Alone or in Combination With Trastuzumab in Women With ErbB2-Positive, Trastuzumab-Refractory Metastatic Breast Cancer
- (2010) Kimberly L. Blackwell et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Trial of Continuous Dose-Intense Temozolomide in Recurrent Malignant Glioma: RESCUE Study
- (2010) James R. Perry et al. JOURNAL OF CLINICAL ONCOLOGY
- Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial
- (2010) Axel Le Cesne et al. LANCET ONCOLOGY
- Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial
- (2010) François-Xavier Mahon et al. LANCET ONCOLOGY
- Reversible Epithelial to Mesenchymal Transition and Acquired Resistance to Sunitinib in Patients with Renal Cell Carcinoma: Evidence from a Xenograft Study
- (2010) H. J. Hammers et al. MOLECULAR CANCER THERAPEUTICS
- Potent Preclinical Impact of Metronomic Low-Dose Oral Topotecan Combined with the Antiangiogenic Drug Pazopanib for the Treatment of Ovarian Cancer
- (2010) Kae Hashimoto et al. MOLECULAR CANCER THERAPEUTICS
- Diverse somatic mutation patterns and pathway alterations in human cancers
- (2010) Zhengyan Kan et al. NATURE
- Rechallenging with anthracyclines and taxanes in metastatic breast cancer
- (2010) Carlo Palmieri et al. Nature Reviews Clinical Oncology
- Efficacy of Trastuzumab in Routine Clinical Practice and After Progression for Metastatic Breast Cancer Patients: The Observational Hermine Study
- (2010) J.-M. Extra et al. ONCOLOGIST
- Sunitinib in Patients with Advanced Hepatocellular Carcinoma after Progression under Sorafenib Treatment
- (2010) Marcus Alexander Wörns et al. ONCOLOGY
- Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma
- (2010) Riccardo Lencioni et al. SEMINARS IN LIVER DISEASE
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
- (2009) J. D. Wolchok et al. CLINICAL CANCER RESEARCH
- Can Chemotherapy Be Discontinued in Unresectable Metastatic Colorectal Cancer? The GERCOR OPTIMOX2 Study
- (2009) Benoist Chibaudel et al. JOURNAL OF CLINICAL ONCOLOGY
- Trastuzumab Beyond Progression in Human Epidermal Growth Factor Receptor 2–Positive Advanced Breast Cancer: A German Breast Group 26/Breast International Group 03-05 Study
- (2009) Gunter von Minckwitz et al. JOURNAL OF CLINICAL ONCOLOGY
- Rechallenge with temozolomide in patients with recurrent gliomas
- (2009) Antje Wick et al. JOURNAL OF NEUROLOGY
- From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors
- (2009) R. L. Wahl et al. JOURNAL OF NUCLEAR MEDICINE
- How Much Is Life Worth: Cetuximab, Non-Small Cell Lung Cancer, and the $440 Billion Question
- (2009) T. Fojo et al. JNCI-Journal of the National Cancer Institute
- Previous best responses can be re-achieved by resumption after imatinib discontinuation in patients with chronic myeloid leukemia: implication for intermittent imatinib therapy
- (2009) Hyun-Gyung Goh et al. LEUKEMIA & LYMPHOMA
- Effect of gefitinib re-challenge to initial gefitinib responder with non-small cell lung cancer followed by chemotherapy
- (2009) Yoshio Tomizawa et al. LUNG CANCER
- Dihydrofolate reductase amplification and sensitization to methotrexate of methotrexate-resistant colon cancer cells
- (2009) C. Morales et al. MOLECULAR CANCER THERAPEUTICS
- Phase II study of erlotinib as a salvage treatment for non-small-cell lung cancer patients after failure of gefitinib treatment
- (2008) D. H. Lee et al. ANNALS OF ONCOLOGY
- Re-induction of hormone sensitivity to diethylstilboestrol in androgen refractory prostate cancer patients following chemotherapy
- (2008) R A Cox et al. BRITISH JOURNAL OF CANCER
- A phase II study investigating the re-induction of endocrine sensitivity following chemotherapy in androgen-independent prostate cancer
- (2008) J Shamash et al. BRITISH JOURNAL OF CANCER
- Temozolomide rechallenge in recurrent malignant glioma by using a continuous temozolomide schedule
- (2008) James R. Perry et al. CANCER
- Stopping Treatment Can Reverse Acquired Resistance to Letrozole
- (2008) G. J. Sabnis et al. CANCER RESEARCH
- Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer
- (2008) J. A. Engelman et al. CLINICAL CANCER RESEARCH
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
- Bevacizumab Beyond First Progression Is Associated With Prolonged Overall Survival in Metastatic Colorectal Cancer: Results From a Large Observational Cohort Study (BRiTE)
- (2008) Axel Grothey et al. JOURNAL OF CLINICAL ONCOLOGY
- Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group
- (2008) Howard I. Scher et al. JOURNAL OF CLINICAL ONCOLOGY
- A Threefold Dose Intensity Treatment With Ifosfamide, Carboplatin, and Etoposide for Patients With Small Cell Lung Cancer: A Randomized Trial
- (2008) S. Leyvraz et al. JNCI-Journal of the National Cancer Institute
- Lung Cancer Response to Gefitinib, Then Erlotinib, Then Gefitinib Again
- (2008) Alvin S. Wong et al. Journal of Thoracic Oncology
- Dynamic Proteomics of Individual Cancer Cells in Response to a Drug
- (2008) A. A. Cohen et al. SCIENCE
- Intermittent androgen blockade should be regarded as standard therapy in prostate cancer
- (2008) Bostjan Seruga et al. Nature clinical practice. Oncology
- Intermittent chemotherapy in patients with metastatic androgen-independent prostate cancer
- (2007) Tomasz M. Beer et al. CANCER
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started